Abstract
Mergers and acquisitions (M&A) as a strategy has been used increasingly by the corporate sector to gain a competitive advantage. Mergers and acquisitions (M&A) help a firm gain new customer bases, enter new markets, gain access to new technologies, and help achieve cost reduction. In today’s time, firms try to achieve synergistic gains through M&As. This study aimed to: a) understand if prices paid by acquiring firms reflected synergistic gains and b) observe value created for shareholders of the acquiring firms. The study used secondary data for the purpose of research. A neural network model was built to scrutinize the impact of the selected variables on the value of the mergers and acquisitions (M&A) deal. An event study was carried out to assess value creation for shareholders of the acquiring firm. The study found that an acquiring firm generally paid more during the M&As compared to the synergistic gains it realized post-acquisition. Additionally, there was no value creation for the acquiring firm’s shareholders. The neural network model from this study, with appropriate variables, can be used to predict the price of an M&A deal. The study will benefit the stakeholders of pharmaceutical firms to make informed decisions regarding mergers and acquisitions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.